Suppr超能文献

在基层医疗环境中完全使用地塞米松治疗的重症 COVID-19 患者的有益治疗结果,包括治疗方案——病例系列报告

Beneficial Treatment Outcomes of Severe COVID-19 Patients Treated Entirely in Primary Care Settings With Dexamethasone Including Regimen-Case Series Report.

作者信息

Vukoja Damir, Jurić Andrea, Erkapić Zdravka, Pejić Tomislav, Zovko Željko, Juričić Josipa, Pejić Jelena, Ćorluka Matea

机构信息

Grude Health Center, Grude, Bosnia and Herzegovina.

Institute for Public Health of West Herzegovina County, Grude, Bosnia and Herzegovina.

出版信息

Front Pharmacol. 2021 Aug 12;12:684537. doi: 10.3389/fphar.2021.684537. eCollection 2021.

Abstract

Even in 2021, coronavirus disease 2019 (COVID-19) remains a major global health concern, especially in developing countries. The burden of this disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which affects not only primary respiratory but also other organ systems, keeps rising as the pandemic continues. Primary health care centers are the first line where COVID-19 patients are managed and should be able to manage the vast majority of them successfully. In this paper, we present a case series and concept of beneficial management of even deteriorating and severe patients treated entirely in our primary health center. The management is based on well-timed and rational dexamethasone use, as well as on various other pharmacological and nonpharmacological treatments and interventions, and is supported by provided statistical data. According to the presented experience and positive outcomes achieved, it seems that even deteriorating and severe COVID-19 patients can be treated successfully to some extent or even completely in primary care settings. This kind of approach could be particularly beneficial in conditions of overload of higher-level health care institutions.

摘要

即使在2021年,2019冠状病毒病(COVID-19)仍然是全球主要的健康问题,尤其是在发展中国家。这种由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的疾病,不仅影响主要呼吸系统,还影响其他器官系统,随着疫情的持续,其负担不断加重。初级卫生保健中心是管理COVID-19患者的第一线,应该能够成功管理绝大多数患者。在本文中,我们介绍了一系列病例以及在我们初级卫生中心完全治疗的病情恶化和重症患者的有益管理理念。该管理基于适时、合理地使用地塞米松,以及其他各种药物和非药物治疗及干预措施,并得到所提供统计数据的支持。根据所呈现的经验和取得的积极成果,似乎即使是病情恶化和重症的COVID-19患者在初级保健环境中也能在一定程度上甚至完全成功得到治疗。在高级别医疗机构超负荷的情况下,这种方法可能特别有益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b537/8387596/16dc22e7cd58/fphar-12-684537-g001.jpg

相似文献

3
Pathogenesis-directed therapy of 2019 novel coronavirus disease.
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
4
6
Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019.
J Comp Eff Res. 2020 Dec;9(18):1247-1254. doi: 10.2217/cer-2020-0146. Epub 2020 Nov 27.
7
COVID-19: a conundrum to decipher.
Eur Rev Med Pharmacol Sci. 2020 May;24(10):5830-5841. doi: 10.26355/eurrev_202005_21378.
8
[Pituitary tumor resection in a patient with SARS-CoV-2 (COVID-19) infection. A case report and suggested airway management guidelines].
Braz J Anesthesiol. 2020 Mar-Apr;70(2):165-170. doi: 10.1016/j.bjan.2020.06.001. Epub 2020 Jun 9.
10

本文引用的文献

1
Human rights and fair access to COVID-19 vaccines: the International AIDS Society-Lancet Commission on Health and Human Rights.
Lancet. 2021 Apr 24;397(10284):1524-1527. doi: 10.1016/S0140-6736(21)00708-X. Epub 2021 Mar 24.
2
Successful implementation of modern critical care in the low-resources country Bosnia and Herzegovina : Single-center experience.
Med Klin Intensivmed Notfmed. 2022 May;117(4):269-275. doi: 10.1007/s00063-021-00778-4. Epub 2021 Jan 24.
3
Rationale for azithromycin in COVID-19: an overview of existing evidence.
BMJ Open Respir Res. 2021 Jan;8(1). doi: 10.1136/bmjresp-2020-000806.
4
Natural history of COVID-19 and therapeutic options.
Expert Rev Clin Immunol. 2020 Dec;16(12):1159-1184. doi: 10.1080/1744666X.2021.1847640. Epub 2020 Dec 24.
5
Obesity population at risk of COVID-19 complications.
Glob Health Epidemiol Genom. 2020 Nov 6;5:e6. doi: 10.1017/gheg.2020.6. eCollection 2020.
6
Insights From Rapid Deployment of a "Virtual Hospital" as Standard Care During the COVID-19 Pandemic.
Ann Intern Med. 2021 Feb;174(2):192-199. doi: 10.7326/M20-4076. Epub 2020 Nov 11.
7
Sex differences in COVID-19 case fatality: do we know enough?
Lancet Glob Health. 2021 Jan;9(1):e14-e15. doi: 10.1016/S2214-109X(20)30464-2. Epub 2020 Nov 5.
8
Explaining among-country variation in COVID-19 case fatality rate.
Sci Rep. 2020 Nov 3;10(1):18909. doi: 10.1038/s41598-020-75848-2.
10
COVID-19: Discovery, diagnostics and drug development.
J Hepatol. 2021 Jan;74(1):168-184. doi: 10.1016/j.jhep.2020.09.031. Epub 2020 Oct 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验